A5081941917- Maternal and fetal healthcare
- Maternal and Perinatal Health Interventions
- Pregnancy and preeclampsia studies
- Ectopic Pregnancy Diagnosis and Management
- Gestational Trophoblastic Disease Studies
- Uterine Myomas and Treatments
- Assisted Reproductive Technology and Twin Pregnancy
- Trauma and Emergency Care Studies
- Pregnancy-related medical research
- Congenital Diaphragmatic Hernia Studies
- Meta-analysis and systematic reviews
- Gestational Diabetes Research and Management
- Neonatal and fetal brain pathology
- Grief, Bereavement, and Mental Health
- Gynecological conditions and treatments
- Preterm Birth and Chorioamnionitis
- Delphi Technique in Research
- Emergency and Acute Care Studies
- Hospital Admissions and Outcomes
- Healthcare Policy and Management
- Clinical practice guidelines implementation
- Neonatal Respiratory Health Research
- Prenatal Substance Exposure Effects
- Venous Thromboembolism Diagnosis and Management
- Palliative Care and End-of-Life Issues
Intermountain Healthcare
2016-2025
University of Utah
2016-2025
University College London
2025
Brigham and Women's Hospital
2025
Columbia University
2025
University of California, San Francisco
2020-2025
Mount Sinai Hospital
2025
Health and Human Development (2HD) Research Network
2018-2023
Primary Children's Hospital
2020-2023
Community Link
2019-2023
To assess the distribution of gestational age at delivery for patients with placenta accreta spectrum (PAS) in United States. This serial cross-sectional study examined 26,375 hospital deliveries a diagnosis code PAS identified Agency Healthcare Research and Quality's Cost Utilization Project National Inpatient Sample from 2016 to 2021. Descriptive analysis was performed evaluate related obstetric characteristics. The incidence codes also assessed among 21,212,493 deliveries. majority...
For decades, placenta accreta spectrum disorder has been classified, staged, and described as a of placental invasion. In this commentary, we argue that exists defective decidua uterine scar dehiscence, not destructive trophoblast Adopting understanding will help direct research efforts clinical resources toward the prevention, accurate diagnosis, safe treatment devastating—and increasingly common—disorder.
Drug-induced deaths, defined as intentional or unintentional consumption of illicit substances diverted medications leading to death, are the cause death for reproductive-age women in United States. Our objective was describe pregnancy-associated deaths attributed drug-induced causes identify opportunities intervention.
Placenta accreta spectrum (PAS) is one of the most dangerous conditions in pregnancy and increasing frequency. The risk life-threatening bleeding present throughout but particularly high at time delivery. Although exact cause unknown, result clear: Severe PAS distorts uterus surrounding anatomy transforms pelvis into an extremely high-flow vascular state. Screening for factors assessing placental location by antenatal ultrasonography are essential timely diagnosis. Further evaluation...
Multiple cesarean deliveries are known to be associated with long-term postoperative consequences because of a permanent defect the lower uterine segment wall and development thick pelvic adhesions. Patients history multiple often present large scar defects at heightened risk in subsequent pregnancies ectopic pregnancy, rupture, low-lying placenta or previa, previa accreta. Moreover, will lead progressive dehiscence inability effectively reapproximate hysterotomy edge repair birth. Major...
Placenta accreta spectrum (PAS) is associated with significant maternal morbidity, but inconsistent outcome reporting across studies hampers meaningful comparisons of management approaches. This statement proposes standardized criteria for measuring severe morbidity and mortality (SMM) PAS, distinguishing true complications from expected interventions in care. Traditional SMM definitions are problematic PAS research because they classify anticipated such as hysterectomy blood transfusions...
Placenta previa is associated with maternal hemorrhage, but most literature focuses on morbidity in the setting of placenta accreta. We aim to characterize and define risk factors for hemorrhage.This a secondary cohort analysis NICHD Maternal-Fetal Medicine Units Network Cesarean Section Registry. This included all women undergoing primary delivery without About 496 were compared 24,201 previa. Primary outcome was composite hemorrhagic morbidity. Non-hemorrhagic morbidities hemorrhage also...
OBJECTIVE: To evaluate placenta accreta spectrum with and without previa regard to risk factors, antepartum diagnosis, maternal morbidity. METHODS: We conducted a retrospective cohort study of pathology-confirmed deliveries hysterectomy from two U.S. referral centers January 2010–June 2019. Maternal, pregnancy, delivery characteristics were compared among cases (previa PAS group) (nonprevia previa. Surgical outcomes composite severe morbidities evaluated, including eight or more blood cell...
OBJECTIVE: To better understand placenta accreta spectrum (PAS) by correlating postoperative ultrasonographic findings of the explanted uteroplacental interface with intraoperative and gross pathology. METHODS: We enrolled consecutive pregnant patients aged 18 years older a prior cesarean delivery antenatal diagnosis lower uterine segment PAS who planned to undergo hysterectomy into this prospective, descriptive study. All underwent standardized photography. Ultrasonography postsurgical...
Abstract Placenta accreta spectrum (PAS) is a high-risk obstetrical condition associated with significant morbidity and mortality. Current clinical screening modalities for PAS are not always conclusive. Here, we report nanostructure-embedded microchip that efficiently enriches both single clustered circulating trophoblasts (cTBs) from maternal blood detecting PAS. We discover uniquely high prevalence of cTB-clusters in subsequently optimize the device to preserve intactness these clusters....
Objective To describe the lived experience of patients undergoing diagnosis and treatment placenta accreta spectrum (PAS). Design Qualitative study semi-structured interviews. A content analysis was used to analyse interview data using a consistent set codes designate segments that contain similar material. Codes were analysed grouped based on thematic similarities. Thematic results systematically reviewed, verified audited address trustworthiness rigour analysis. Setting single PAS...
To evaluate the association between prophylactic ureteral stent placement at time of hysterectomy for placenta accreta spectrum and genitourinary injury.We conducted a retrospective cohort study patients with who underwent two referral centers from 2001 to 2021. The exposure was placement. primary outcome, injury, composite bladder or vesicovaginal fistula. Secondary outcomes included components outcome. We evaluated differences groups using χ 2 t test. in we reported odds ratios (ORs)...
Placenta Accreta Spectrum (PAS) disorders are a complex range of placental pathologies associated with significant maternal morbidity and mortality. Diagnosis PAS relies on ultrasonographic findings modest positive predictive value. Exosomal microRNA (miR) small RNA molecules which reflect the cellular processes origin tissues. We aimed to explore exosomal miR expression understand pathology clinical utility for detection. This study was biomarker analysis prospectively collected samples in...
Short-term morbidity of placenta accreta spectrum (PAS) is well described, but few data are available regarding long-term outcomes and quality life. We aimed to evaluate patient-reported after hysterectomy for PAS.This a prospective cohort study women with risk factors PAS who were enrolled antenatally. Exposed defined as those underwent cesarean due PAS. Unexposed three or more prior cesareans previa, no PAS, delivery without hysterectomy. Two surveys sent patients at 6, 12, 24, 36 months...
OBJECTIVE: To compare the actual health-system cost of elective labor induction at 39 weeks gestation with expectant management. METHODS: This was an economic analysis patients enrolled in five Utah hospitals participating a multicenter randomized trial compared management low-risk nulliparous women. The entire more than 6,000 patients. For this subset, 1,201 had data available. primary outcome relative direct health care costs maternal and neonatal from system perspective. Secondary...